Amifostine for injection

This product is an organic thiophosphate compound. After being hydrolyzed and dephosphorylated by alkaline phosphatase bound to the cell membrane in the tissue, it becomes an active metabolite WR-1065, whose chemical structure is H2N-(CH2)3-NH-(CH2)2-SH. Because the sulfhydryl group has the function of scavenging free radicals in the tissue, it can reduce the toxicity of cisplatin, cyclophosphamide and mitomycin.

Main ingredient: S-2-[3-aminopropylamine]ethylthiophosphoric acid Molecular formula: C5H15N2O3PS Molecular weight: 214.22

This product is a normal cell protective agent, mainly used for the adjuvant treatment of various cancers. The use of this product before chemotherapy for patients with various cancers such as lung cancer, ovarian cancer, breast cancer, nasopharyngeal cancer, bone tumors, digestive tract tumors, and blood system tumors can significantly reduce the toxicity of chemotherapy drugs to the kidneys, bone marrow, heart, ears, and nervous system without reducing the efficacy of chemotherapy drugs. The use of this product before radiotherapy can significantly reduce the occurrence of dry mouth and mucositis.

1 For chemotherapy patients, the starting dose of this product is 500-600 mg/m2 per body surface area, dissolved in 50 ml of 0.9% sodium chloride injection, intravenously dripped 30 minutes before the start of chemotherapy, and dripped in 15 minutes. 2 For radiotherapy patients, the starting dose of this product is 200-300 mg/m2 per body surface area, dissolved in 50 ml of 0.9% sodium chloride injection, intravenously dripped 30 minutes before the start of radiotherapy, and dripped in 15 minutes. 3 Antiemetic therapy is recommended, that is, intravenous injection of 5-10 mg of dexamethasone and 5-HT3 receptor antagonists before and at the same time as this product. 4 If the systolic blood pressure is significantly lower than the baseline value listed in the table, the infusion of this product should be stopped. Baseline systolic blood pressure (mmHg) <100 100～119 120～139 140～179 ≥180 Infusion of this product reduces systolic blood pressure (mmHg) 20 25 30 40 50 If blood pressure returns to normal within 5 minutes and the patient is asymptomatic, the injection can be restarted.

1 Dizziness, nausea, vomiting, fatigue, etc., but patients can tolerate it. 2 During medication, there is a transient slight drop in blood pressure, which generally resolves within 5 to 15 minutes. Less than 3% of patients need to stop medication due to a significant drop in blood pressure. 3 At the recommended dose, less than 1% of patients experience a slight decrease in blood calcium concentration. 4 Some patients may experience mild drowsiness, sneezing, and a warm feeling on the face.

1. Use with caution in patients with hypotension and hypocalcemia. 2. Contraindicated in patients with a history of allergy to this product or allergic to mannitol.

Not yet clear.

Keep in a light-proof, airtight, cool place.